Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rafarma Pharmaceuticals has commenced production of antibiotic Ceftriaxone indicated to treat inflammatory infections of the organs of the abdominal cavity, including peritonitis, in addition to, inflammatory diseases of the gastrointestinal and bile-excreting tracts.
Subscribe to our email newsletter
Produced in Unit 2 of Rafarma’s Terbuni plant, Ceftriaxone formulated for injections will be packed in 10ml bottles with single gram dosages.
With an estimated Ceftriaxone market of more than $51m per year in Russia, as per 2011 official statistics, Rafarma intends to take 50% of the market in the country for the antibiotic.
ZAO "SIA International" and the Russian national retail chain OAO "A5 Pharmacy Ltd." have signed a long-term national and regional distribution contracts with Rafarma.
Rafarma CEO David Anderson said with 17 national distributors signing long-term agreements, the company’s production and penetration of market share remains assured.
"These contracts were an integral part of Rafarma’s expansion plan and will play a vital role in the expansion of operations. Rafarma has positioned itself to become one of the five leading pharmaceutical companies in the Russian Federation," Anderson added.